Gynecologic Oncology News & Updates

A compilation of news articles in the field of gynecologic oncology and recent scientific studies

 

Opioid use common among cancer survivors
August 7, 2017: Healio reports: “Cancer survivors, even those 10 years or longer past diagnosis, had 1.22-times higher prescription opioid use than matched individuals without a history of cancer, according to results of a population-based study.” Read the Healio article. Read the original study.

New data address critical surgical questions in ovarian cancer
August 4, 2017: Dr. Maurie Markman discusses two abstracts presented at the 2017 ASCO meeting: LION Study (Lymphadenectomy in Ovarian Neoplasms) and Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Watch the video or read the transcript.

Surgeons and the opioid epidemic: Treatment and education strategies for the practicing surgeon
August 2, 2017: The American College of Surgeons released a bulletin to address issues surgeons are facing regarding opioids. The bulletin includes Implicit bias and the perception of pain, opioid treatment of chronic pain, opioid management training and a general approach to improved treatment of surgical pain. Read the bulletin.

Celsion announces latest translational data from the OVATION Study in newly diagnosed advanced ovarian cancer patients
August 2, 2017: Nasdaq reports: “findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy (NACT) followed by interval debulking surgery.” Read the press release.

Lower body lymphedema in patients with gynecologic cancer
August 2017: This International Journal of Cancer Research and Treatment review “focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment.” Read the study.

77-year-old cancer patient undergoes robotic surgery
July 31, 2017: The Times of India reports the benefits of robotic surgery and an instance in which it was used for an ovarian cancer patient. Read the article. 

Bristol-Myers Squibb, Clovis Oncology to evaluate nivolumab-rucaparib combination
July 31, 2017: Healio reports: Bristol-Myers Squibb and Clovis Oncology entered a clinical collaboration to evaluate the combination of nivolumab and rucaparib for treatment of three tumor types. The collaboration will include two pivotal phase 3 trials and one phase 2 trial designed to assess the PD-1 checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in combination with the PARP inhibitor rucaparib. Read more.

Is it possible to get pregnant after endometrial cancer? An oncologist explains
July 30, 2017: Kelly Mullen McWilliams blogs about uterine cancer and pregnancy. Read the blog.

Molecular similarities discovered among endometrial cancers
July 28, 2017: Healio reports: “Clear cell endometrial cancer appeared to have molecular similarities with serous endometrial cancer and endometrioid endometrial cancer, according to a study published in Cancer.” Read the article.

Researchers to present clinical data supporting use of Xoft System for endometrial cancer treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
July 27, 2017: EconoTimes reports: “Researchers from Miguel Servet University Hospital in Zaragoza, Spain will present preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by treatment with Ir-192 or Co-60 sources.” Read more.

Challenges in international comparison of health care systems
July 27, 2017: The JAMA Netowrk published a “viewpoint” article on the differences between health care systems across the globe and how they can be compared despite these differences. Read the article.

Complementary cancer therapies: fatigue and exercise
July 27, 2017: Cure Today published an opinion piece on the positive impact of exercise for cancer patients and survivors. Read the article.

Olaparib tablets prolong progression-free survival in ovarian cancer
July 26, 2017: Cancer Therapy Advisor reports: “Maintenance treatment with olaparib tablets may prolong progression-free survival (PFS) without negatively affecting quality of life among patients with relapsed ovarian cancer, according to a study published in The Lancet Oncology.Read more

How PARP inhibitors might prove useful in more than just BRCA cancers
July 26, 2017: FierceBiotech reports: “Scientists led by the University of Pennsylvania believe Lynparza may be able to kill cancer cells that don’t have the mutations—provided it’s paired with a helper compound.” Read more.

Cancer patients in chemo ward may influence each other’s survival
July 25, 2017: Reuters Health reports: “Who a cancer patient spends time with in the chemotherapy ward may have a small but significant effect on their likelihood of surviving the disease, suggests a small study in the UK.” Read the article.

Doctors receiving training in cervical cancer surgery
July 24, 2017: The Himalayan Times report that “doctors of Bhaktapur Cancer Hospital and Nepal Cancer Relief Society have been undergoing surgical training in gynecologic oncology from Health Volunteers Overseas, USA.” Read more.

Breast cancer due to non-brca1 and non-BRCA2 mutations in Ashkenazi Jewish Women
July 20, 2017: JAMA Network posts an audio file of an interview with Mary-Claire King, author of Genetic Predisposition to Breast Cancer Due to Mutations other than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Listen to the interview. 

Nivolumab active in advanced gynecologic cancers
July 19, 2017: Onc Live reports: from ASCO 2017: “In phase I/II results from CheckMate-358, nivolumab (Opdivo) demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.” Read more.

Task force maintains recommendation against ovarian cancer screening
July 18, 2017: Drs. Maurie Markman and Richard Penson agree with the US Preventative Services Task Force advising “against screening for ovarian cancer in women who have no signs or symptoms, noting that screening does not decrease the number of deaths from ovarian cancer and may lead to women having unnecessary surgery.” Read more.

FDA ODAC recommends biosimilar bevacizumab and trastuzumab
July 18, 2017: The European Society for Medical Oncology reports the recent FDA recommendation regarding these two drugs. Read more.

Preventative mastectomies provide little survival benefit for ovarian cancer patients, study finds
July 17, 2017: Ovarian Cancer News Today reports: “Mastectomies and the removal of ovaries and fallopian tubes are considered preventive measures for women carrying BRCA genetic mutations linked to breast and ovarian cancer. But for women who have already had ovarian cancer, a risk-reducing mastectomy is not cost-effective and provides few survival benefits, according to researchers at Duke University Medical Center.” Read more.

Rethinking the ASCO Resource Stratified Cervical Cancer Screening Guidelines in the context of existing health infrastructure in basic settings
July 17, 2017: The Journal of Clinical Oncology publishes a response to the ASCO guideline challenging two of the recommendations the believe overlook opportunities to use existing health infrastructure in low- and middle-income countries. Read the correspondence.

With cancer screening, better safe than sorry?
July 17, 2017: The New York Times editorial discusses the risks and benefits of cancer screening as well as providing a list of US screening guidelines for different cancers. Read the article.

High-grade dysplasia increases long-term risk for HPV-related cancers
July 17, 2017: Healio.com reports: “Women maintained an increased risk for premalignancies and carcinomas of the anus, vulva, vagina and oropharynx 20 years after cervical intraepithelial neoplasia grade 3 diagnosis, according to results of a population-based study.” Read more.

Novel agent produces highest OS to date in PRmCC
July 14, 2017: Clinical Oncology reports: “Data from a multicenter trial of a novel targeted immunotherapy for the treatment of persistent/recurrent or metastatic cervical cancer (PRmCC) have yielded historic results: a 12-month overall survival (OS) of 38%, exceeding OS rates of more than 20 other clinical trials conducted in this area over nearly two decades.” Read more.

Cervical Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
July 13, 2017: Annals of Oncology publishes ESMO cervical cancer guidelines focusing on the management, follow-up, long term implications and survivorship as well as a new treatment algorithm. Read the guidelines.

Clinical trials are the way forward for ovarian cancer, but they need advocates at every level
July 9, 2017: Cure Today reports: “For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.” Read more.

The road ahead for ovarian cancer
July 8, 2017: Cure today reports: “Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.” Read the full article with more quotes from Dr. Moroney.

Incidence and prevalence of cancer in Colombia: the methodology used matters
July 6, 2017: Study published in ASCO’s Journal of Global Oncology compares real-world data from the health care system and estimates from cancer registries to determine a more precise estimation of patients with cancer in Colombia. Read the study.

Rates of pregnancy significantly lower in cancer survivors compared with general population
July 6, 2017: Oncology nurse advisor reports: A large scale population study revealed that girls and women aged 39 years and younger may be up to 38% less likely to achieve pregnancy after surviving cancer vs patients who have never had cancer. Read more.

Web-based symptom self-reporting improves survival
July 6, 2017: ClinicalOncology.com reports: “Having patients proactively report symptoms through a web-based tool improved survival in patients receiving routine outpatient chemotherapy, according to results from a Phase III trial. The approach increased median overall survival by five months compared with usual care.” Read more.

HPV triage after abnormal cervical cytology detects CIN earlier
July 5, 2017: Cancer Network reports “Women who undergo human papillomavirus (HPV) testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia (CIN), compared to those who do not undergo HPV testing, according to a new study. The higher rates of detection come at the expense of increased biopsy and electrosurgical excision rates.” Read more.

Angle’s ovarian cancer test could beat current standard
July 5, 2017: “UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.” Read more.

PARP inhibitor shows promise in ovarian cancer
July 5, 2017: “Results of the ARIEL3 study of rucaparib (Rubraca) show promise for the drug’s potential in helping women with advanced ovarian cancer, according to Boulder, Colo.-based Clovis Oncology, a biopharmaceutical company that specializes in cancer treatments.” Read more.

Celsion announces completion of OVATION study and provides update on its immunotherapy trial in advanced stage III and IV ovarian cancer
July 5, 2017: GlobeNewswire reports “Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.” Read the announcement.

FDA grants orphan drug designation to ALM201 for ovarian cancer
July 5, 2017: Healio.com announces: “ALM201 (Almac Discovery) is a therapeutic peptide developed to imitate properties of the FKBPL protein, a naturally secreted protein that has effects on multiple tumor biology processes, including cancer stem cells and angiogenesis.” Read the announcement.

Read archived news stories.

Awards & Recognition

August, 2017: Dr. Andreas Obermair (IGCS Secretary-Treasurer Elect) and Ms. Paula Benson received the 2017 Jeannie Ferris Cancer Australia Recognition Award for their outstanding contributions to improving outcomes for women with gynaecological cancers. Read more about this award.

 

 

 

 

IGCS celebrates the awards and recognition of its members. If you have recently received an award or know someone who has, please let us know by emailing Debbie.leopold@igcs.org.

 

Member Testimonials

As we lead up to the 30th Anniversary of the first IGCS Biennial Meeting, we want to hear from you (IGCS Members) regarding the impact IGCS has had on your professional life. This year, 2017, is the 30th Anniversary of the first-ever IGCS Biennial Meeting which was held in Amsterdam October 4-6, 1987. Over the next several months, we plan to celebrate IGCS’s achievements and the societies’ impact on its members over the years. We hope that you will help us do this in one of the following ways:

  1. Send us a written statement regarding your experience with the IGCS with a photograph of yourself. 2-3 sentences are sufficient but if you wish to write more, we’d like to hear it. The photograph does not need to be professional, but it should clearly show your face and have some space in the background around your face (not a “tight” shot).
  2. Record a short video clip of yourself regarding your experience with the IGCS or your opinion regarding the society and it’s impact to the global gynecologic cancer community. The video clip can be recorded on any device – send us the file and we will post it. You can use your phone, computer, or other video camera. If using a phone or tablet, please turn it on it’s side for a wide shot instead of a tall shot. Test the lighting and see what looks best in your recording. Usually natural lighting near a window or outside looks nice on video.

These statements and videos will be shared on the IGCS website and on social media here: https://igcs.org/our-impact/ and here: https://igcs.org/igcs-member-videos/ 

Some helpful tips when preparing your statement are listed below and in the video below, IGCS Communications Manager, Debbie Leopold provides some helpful tips as well.

In your video or written quote, some suggested topics include:

1. Explain the impact IGCS and its programs or meetings have had on your professional life.
2. Explain why you became a member of the IGCS and/or why you will continue to be a member.
3. Tell us your opinion on the work IGCS has done or is currently doing.

If you are recording yourself, it may help you to write down what you plan to say before recording. Please begin the recording by stating your name, institution, city and country.

Please send your quotes, photograph and/or videos to debbie.leopold@igcs.org.

 

IGCS: Past, Present, Future

Dear Colleagues,

This year in October marks thirty years since the first IGCS Biennial Meeting which was held in Amsterdam October 4-6, 1987. I have been involved with this great society since it was formed all those years ago – I am proud of the work it has done in the past, the present commitment of the leadership and the promise the future holds. IGCS started with 370 attendees at that first meeting and has steadily grown over time. At our most recent Biennial Meeting in Lisbon, Portugal October 28-31, 2016, we brought over 2,500 gynecologic oncology professionals together from over 80 countries to share knowledge, exchange ideas and to make lasting connections.

Education, training and mentorship has always been at the heart of IGCS’s mission. IGCS brings people together at its Biennial Meetings, and previously at Regional Meetings. We now work extensively with local societies by participating in more frequent, smaller collaborative meetings across the globe. Just this year, we have participated in six such regional meetings and we plan to collaborate with several more in the near future by providing guest lecturers and/or educational forums.

IGCS has a history of facilitating education and training to doctors in regions that do not have a formal training program in gynecologic oncology. The society has provided financial support to countless scholars over the years so they could travel to a host institution to observe and receive training and mentorship. This program has transitioned into the IGCS Gynecologic Oncology Global Curriculum & Mentorship Program, a comprehensive two-year education and training program. With this new program, it is our goal to train even more doctors and have a greater positive impact on the global women’s cancer community. Fellows at pilot sites in Vietnam and Mozambique have begun the curriculum and received visits from their mentors. We are still seeking additional volunteer mentors to participate in this program and I will be sending out a survey to you soon about this.

IGCS is proud to have always welcomed and encouraged a multidisciplinary team of health care providers dedicated to the treatment of women’s cancer. Lasting connections have certainly been made among our members, primarily though attendance at Biennial Meetings. Presently, also, there is a unique opportunity for growth to carry our global community into the future. The new Strategic Alliance Partnership Program will welcome regional organizations and groups to join the IGCS as a unified cohort. Belarus has recently become a partner and we hope to see more networking among our members with this new model.

Through communication and collaboration among IGCS’s individual members, leadership, industry and partner organizations, IGCS will continue to thrive in the coming years and beyond. The newly designed IGCS website provides our members with easy access to educational resources such as the International Journal of Gynecological Cancer, recordings of presentations, surgical videos and much more to come. IGCS is taking the next step in virtual connection and is currently exploring methods to allow members to discuss topics in an online social community. Meanwhile, the Education Committee is working hard to develop innovative programs to enhance our online learning opportunities.

We are currently working to create photo galleries on the new IGCS website which we will share with you all in the coming weeks. I am delighted to let you know that Professor Peter Heintz from Holland who hosted the very first meeting of IGCS 30 years ago has agreed to chair a new Archives Committee. Archives are much more than memories. They remind us of where we came from, where we have been and how far we have developed in our outreach to women.

We invite you all to share your photographs and memories to help IGCS celebrate its 30th Anniversary. We are seeking written quotes and videos from members and I ask that you please email the IGCS Communications Manager, at Debbie.leopold@igcs.org if you would like to share a quote, send photographs or record a video.

Thank you for being a member of the IGCS. We look forward to continuing our mission to enhance the care of women with gynecologic cancer worldwide through education and training and public awareness for many more years to come. It is interesting to conjecture just how the care of women with gynecological cancers will have changed in 30 years’ time. Let’s hope it will be unrecognizable!

Sincerely,

 

 

Michael Quinn, MA, MGO
2016-2018 IGCS President

 

New Education Exchanges Available

Five new Education Exchange Videos have been posted in the IGCS Education Portal. Recorded at the 2016 Biennial Meeting in Lisbon, Portugal, these Education Exchanges allow thought leaders in the field of gynecologic oncology to share information in a brief video format. The newly added videos can be accessed at the following links below. If you are not currently logged in to the IGCS website, you will need you username (email address) and password. Pleases email info@igcs.org if you need assistance.

Dr. Alessandro Buda (Italy) discusses his abstract “From Conventional Radiocolloid Plus Blue Dye To Indocyanine Green (Icg): An European Multicenter Comparison Of Methods Towards The Optimization In SN Mapping Of Cervical Cancer”
Dr. Michael Birrer (USA) speaks about whether ovarian cancer patients can be selected for anti-angiogenic therapy.
Dr. Raimundo Correa (Chile) discusses the importance of palliative care being integrated into the multicenter care team.
Dr. Sven Mahner (Germany) provides an overview of recent progress and game changers leading to more personalized surgical approaches
Dr. Michael Quinn (Australia) discusses the role of the Pap smear in the follow up of endometrial and cervical cancer.

We hope you enjoy these recently added videos and take a few moments to explore the additional content within the IGCS Education Portal including surgical videos and recorded presentations from the 2014 and 2016 Biennial Meetings.

Read the Current Issue of IJGC

ijgc_logotxt

IJGC is the scientific publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. The list of associate editors represents every part of the globe and all the major disciplines involved in treating cancer. Preview the current issue (July, 2017) table of contents here.

IGCS Members
Sign in to the IGCS Member Portal and click through to the Journal to gain full access to the articles.

Read “Featured Article” Blogs written by IGCS Education Committee Members.

N0t an IGCS Member?
Join today to obtain online access to IJGC.

New Members June 2017

Welcome to the New Members who have joined since March, 2017!

Dr. Alison Freimund Australia Medical Oncologist
Dr. Nisha Jagasia Australia Gynecologic Oncologist
Dr. Maryam Husain Bahrain Gynecologic Oncologist
Ms. Mileide Sousa Brazil Fellow-in-Training
Dr. Anna Plotkin Canada Pathologist
Dr. Elisa Orlandini Chile Gynecologic Oncologist
Dr. Sven Becker Germany Gynecologic Oncologist
Dr. Thomas Konney Ghana Gynecologic Oncologist
Dr. Erzsébet Szatmári Hungary OB/GYN
Dr. Dweep Jindal India Gynecologic Oncologist
Dr. Ragini Mehrotra India OB/GYN
Dr. Swasti Swasti India Gynecologic Oncologist
Dr. Veena P India Gynecologic Oncologist
Dr. Donal Brennan Ireland Gynecologic Oncologist
Dr. Luz Rivas Mexico Gynecologic Oncologist
Dr. Roberto Romero Mexico Medical Oncologist
Dr. Dercia Changule Mozambique Resident
Dr. Anju Shrestha Nepal Gynecologic Oncologist
Dr. Dorry Boll Netherlands Gynecologic Oncologist
Dr. Oluwadare Adepetu Nigeria Fellow-in-Training
Dr. Angelica Stephanie Munoz Philippines OB/GYN
Dr. Donalyn Barcial Philippines Fellow-in-Training
Dr. Dagmara Klasa-Mazurkiewicz Poland Gynecologic Oncologist
Dr. Gavrilov Mikhail Russia Gynecologic Oncologist
Dr. Matsiane Luciah Lekala South Africa OB/GYN
Dr. Nataliya Tsip Ukraine Gynecologic Oncologist
Dr. Mohamed Otify United Kingdom Resident
Mr. Satyam Kumar United Kingdom Fellow-in-Training
Dr. Jvan Casarin United States Fellow-in-Training
Dr. Kevin Elias United States Gynecologic Oncologist
Dr. Larissa Meyer United States OB/GYN
Dr. Matthew Schlumbrecht United States Gynecologic Oncologist
Dr. Tri Dinh United States Gynecologic Oncologist

New WHO Director Elected

IGCS congratulates the newly elected Director General of the World Health Organization, Dr. Tedros Adhanom Ghebreyesus.

The new Director was elected on May 23, 2017 and will begin his five year term on July 1, 2017. Dr. Tedros Adhanom Ghebreyesus was previously the Minister of Health and the Minister of Foreign Affairs in Ethiopia as well as serving as Chairman of multiple health related boards. According to the WHO press release, “As Minister of Health, Ethiopia, Dr. Tedros Adhanom Ghebreyesus led a comprehensive reform effort of the country’s health system, including the expansion of the country’s health infrastructure, creating 3,500 health centres and 16,000 health posts; expanded the health workforce by 38,000 health extension workers; and initiated financing mechanisms to expand health insurance coverage.” His accomplishments are great and are further detailed in the WHO press release.

 

President’s Perspective May 2017

Dear Colleagues,

Two months ago, I was privileged to speak at the 2017 meeting of the Royal College of Obstetricians and Gynaecologists’ (RCOG) in Cape Town about our global curriculum and training programme. At the same meeting, our former President, Lynnette Denny gave a wonderful plenary lecture highlighting the huge health care inequalities between the first and third worlds and emphasised that a diagnosis of cervical cancer, the leading cause of death of women from cancer in emerging countries, leads to loss of employment and income and a major deterioration of living standards.

Since few countries have a nationalised health system, payment for cancer care further pushes women and their families into severe poverty with a significant increase in food insecurity, loss of housing and major absences of children from school. And we all know that education is really the best tool to lead children out of poverty.

In many poor communities, the death of a mother is a major determinant of survival of her infants and children. One telling statistic from Bangladesh noted that cumulative survival from birth to 10 years was only 24% in families where the mother died before the child’s 10th birthday vs. 89% in those whose mothers did not die. How can we not be moved?

Lyn described cancer care in developing countries as ‘abysmal’ and unrecognised as a public health problem. In Africa the incidence to mortality ratio of cancer is 80% compared with 36% in wealthy countries. She highlighted lack of health care and training as important contributors to this awful statistic.

Tanzania is another example where lack of trained personnel and lack of equipment leads to desperate outcomes. For over 20,000 new cases of cancer annually there is one medical oncologist, four radiation oncologists, two physicists and an estimated 5 pathologists. Needless to say trained gynaecological oncologists are few on the ground, if at all.

Africa is not alone when we think of these terrible statistics.

So where does IGCS stand in all of this? Do we have a responsibility to try and change this disparity or is it too hard and best dealt with by someone else?

The answer is of course, that as caregivers and global citizens we do indeed have such a responsibility and that we need to show leadership and commitment. We undoubtedly can make a difference in the arena of education and training. After all, our mission revolves around improving outcomes for women with gynaecological cancers through teaching and training.

For us in the first world, it is time to give back.

The best way for us to do this is to support the IGCS Global Curriculum and Mentorship Programme. This programme depends on volunteer mentors being willing to regularly assess our trainees progress online, spend 1-2 weeks over a two-year period visiting them in their own training institutions and being involved in their exit examination.

By ‘twinning’ mentors and their institutions with training sites we hope that an ongoing rapport and willingness to help will make a huge difference to the care of women in under-developed countries.

In the next few months, IGCS will be reaching out to our members to assess just how many will be willing to join this programme and give back. I encourage you to ponder how well-off you really are and have become, often as a result of your professional status. It’s time for a change. It really is time to give back. Let IGCS lead the way. Please. 

Sincerely,

Michael Quinn, MA, MGO
2016-2018 IGCS President

World Ovarian Cancer Day

Ovarian cancer is the seventh most commonly diagnosed cancer in women worldwide with over 250,000 new cases a year. May 8, 2017 is the 5th World Ovarian Cancer Day – a day in which organizations around the world unite to educate their communities about ovarian cancer and its symptoms. Education and awareness continue to be our best defense against this devastating disease. IGCS is committed to raising awareness to early diagnosis and to reducing the burden of ovarian cancer by ensuring clinicians and women are fully informed about  symptomatology and the benefits of prophylactic surgery in high risk women.

This day provides us with an excellent opportunity to amplify the conversation among IGCS Members who conduct research in the prevention and treatment of ovarian cancer, especially considering the number of breakthroughs regarding ovarian treatment therapies over the last several years. The IGCS Education Committee has selected the following new Education Exchange video clips to release on World Ovarian Cancer Day including:

  • Roberto Angioli discussing ovarian cancer follow-up strategies and clinical uses of tumor markers.
  • Ayelet Shai discussing her abstract presented at IGCS 2016 “The effect of aspirin, statins, metformin and metabolic co-morbidities on the prognosis of patients with ovarian cancer
  • Jalid Sehouli discussing biomarkers in ovarian cancer immunotherapy clinical trials
  • Ignace Vergote discussing his abstract presented at IGCS 2016 “Meta-analysis of the randomized EORTC and chorus neoadjuvant vs. primary debulking trials in advanced tubo-ovarian cancer.

IGCS continues to make education and training top priorities and hope that you have taken the time to view some of the additional excellent education in ourmember education portal.

WorldOvarianCancerDay.org unites advocacy groups worldwide and provides excellent resources for patient materials including key symptoms and risk factors for ovarian cancer and personal stories from dozens of survivors. We encourage you to review these informative materials and share them with your colleagues, patients and communities.

As we continue to strive to be THE global gynecologic oncology organization, we are confident that each of you will continue to play a vital role in continuing to increase the care for women afflicted with gynecologic cancers. We must continue to challenge ourselves and strive to be an impactful organization in relieving the burden of cancer globally.
We look forward to our continued partnership with you, our members. Together, we are better.
 
Michael Quinn, AM, MGO
IGCS President 
 
Mary Eiken, RN, MS
IGCS CEO